SrasV1, PubMed, Checkpoint, bibRecord, 002685

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.

Identifieur interne : 002685 ( PubMed/Checkpoint ); précédent : 002684; suivant : 002686

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.

Auteurs : Heike Hofmann [Allemagne] ; Krzysztof Pyrc ; Lia Van Der Hoek ; Martina Geier ; Ben Berkhout ; Stefan Pöhlmann

Source :

Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 2005.

RBID : pubmed:15897467

Descripteurs français

English descriptors

KwdEn :
- Carboxypeptidases (metabolism), Cell Line, Coronavirus 229E, Human (metabolism), Coronavirus Infections (metabolism), Flow Cytometry, Humans, Membrane Glycoproteins (metabolism), Neutralization Tests, Peptidyl-Dipeptidase A, Plasmids (genetics), Receptors, Virus (metabolism), Respiratory Tract Diseases (virology), SARS Virus (metabolism), Species Specificity, Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (metabolism).
MESH :
- chemical , metabolism : Carboxypeptidases, Membrane Glycoproteins, Receptors, Virus, Viral Envelope Proteins.
- genetics : Plasmids.
- metabolism : Coronavirus 229E, Human, Coronavirus Infections, SARS Virus.
- virology : Respiratory Tract Diseases.
- Cell Line, Flow Cytometry, Humans, Neutralization Tests, Peptidyl-Dipeptidase A, Species Specificity, Spike Glycoprotein, Coronavirus.

Abstract

Coronavirus (CoV) infection of humans is usually not associated with severe disease. However, discovery of the severe acute respiratory syndrome (SARS) CoV revealed that highly pathogenic human CoVs (HCoVs) can evolve. The identification and characterization of new HCoVs is, therefore, an important task. Recently, a HCoV termed NL63 was discovered in patients with respiratory tract illness. Here, cell tropism and receptor usage of HCoV-NL63 were analyzed. The NL63 spike (S) protein mediated infection of different target cells compared with the closely related 229E-S protein but facilitated entry into cells known to be permissive to SARS-CoV-S-driven infection. An analysis of receptor engagement revealed that NL63-S binds angiotensin-converting enzyme (ACE) 2, the receptor for SARS-CoV, and HCoV-NL63 uses ACE2 as a receptor for infection of target cells. Potent neutralizing activity directed against NL63- but not 229E-S protein was detected in virtually all sera from patients 8 years of age or older, suggesting that HCoV-NL63 infection of humans is common and usually acquired during childhood. Here, we show that SARS-CoV shares its receptor ACE2 with HCoV-NL63. Because the two viruses differ dramatically in their ability to induce disease, analysis of HCoV-NL63 might unravel pathogenicity factors in SARS-CoV. The frequent HCoV-NL63 infection of humans suggests that highly pathogenic variants have ample opportunity to evolve, underlining the need for vaccines against HCoVs.

DOI: 10.1073/pnas.0409465102
PubMed: 15897467

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002735
to stream PubMed, to step Curation: 002735

Links to Exploration step

pubmed:15897467

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.</title>
<author><name sortKey="Hofmann, Heike" sort="Hofmann, Heike" uniqKey="Hofmann H" first="Heike" last="Hofmann">Heike Hofmann</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Clinical and Molecular Virology and Nikolaus Fiebiger Center, University Erlangen-Nürnberg, 91054 Erlangen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Clinical and Molecular Virology and Nikolaus Fiebiger Center, University Erlangen-Nürnberg, 91054 Erlangen</wicri:regionArea>
<wicri:noRegion>91054 Erlangen</wicri:noRegion>
<placeName><settlement type="city">Erlangen</settlement>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Moyenne-Franconie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pyrc, Krzysztof" sort="Pyrc, Krzysztof" uniqKey="Pyrc K" first="Krzysztof" last="Pyrc">Krzysztof Pyrc</name>
</author>
<author><name sortKey="Van Der Hoek, Lia" sort="Van Der Hoek, Lia" uniqKey="Van Der Hoek L" first="Lia" last="Van Der Hoek">Lia Van Der Hoek</name>
</author>
<author><name sortKey="Geier, Martina" sort="Geier, Martina" uniqKey="Geier M" first="Martina" last="Geier">Martina Geier</name>
</author>
<author><name sortKey="Berkhout, Ben" sort="Berkhout, Ben" uniqKey="Berkhout B" first="Ben" last="Berkhout">Ben Berkhout</name>
</author>
<author><name sortKey="Pohlmann, Stefan" sort="Pohlmann, Stefan" uniqKey="Pohlmann S" first="Stefan" last="Pöhlmann">Stefan Pöhlmann</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:15897467</idno>
<idno type="pmid">15897467</idno>
<idno type="doi">10.1073/pnas.0409465102</idno>
<idno type="wicri:Area/PubMed/Corpus">002735</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002735</idno>
<idno type="wicri:Area/PubMed/Curation">002735</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002735</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002685</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002685</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.</title>
<author><name sortKey="Hofmann, Heike" sort="Hofmann, Heike" uniqKey="Hofmann H" first="Heike" last="Hofmann">Heike Hofmann</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Clinical and Molecular Virology and Nikolaus Fiebiger Center, University Erlangen-Nürnberg, 91054 Erlangen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Clinical and Molecular Virology and Nikolaus Fiebiger Center, University Erlangen-Nürnberg, 91054 Erlangen</wicri:regionArea>
<wicri:noRegion>91054 Erlangen</wicri:noRegion>
<placeName><settlement type="city">Erlangen</settlement>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Moyenne-Franconie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pyrc, Krzysztof" sort="Pyrc, Krzysztof" uniqKey="Pyrc K" first="Krzysztof" last="Pyrc">Krzysztof Pyrc</name>
</author>
<author><name sortKey="Van Der Hoek, Lia" sort="Van Der Hoek, Lia" uniqKey="Van Der Hoek L" first="Lia" last="Van Der Hoek">Lia Van Der Hoek</name>
</author>
<author><name sortKey="Geier, Martina" sort="Geier, Martina" uniqKey="Geier M" first="Martina" last="Geier">Martina Geier</name>
</author>
<author><name sortKey="Berkhout, Ben" sort="Berkhout, Ben" uniqKey="Berkhout B" first="Ben" last="Berkhout">Ben Berkhout</name>
</author>
<author><name sortKey="Pohlmann, Stefan" sort="Pohlmann, Stefan" uniqKey="Pohlmann S" first="Stefan" last="Pöhlmann">Stefan Pöhlmann</name>
</author>
</analytic>
<series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
<idno type="ISSN">0027-8424</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Carboxypeptidases (metabolism)</term>
<term>Cell Line</term>
<term>Coronavirus 229E, Human (metabolism)</term>
<term>Coronavirus Infections (metabolism)</term>
<term>Flow Cytometry</term>
<term>Humans</term>
<term>Membrane Glycoproteins (metabolism)</term>
<term>Neutralization Tests</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Plasmids (genetics)</term>
<term>Receptors, Virus (metabolism)</term>
<term>Respiratory Tract Diseases (virology)</term>
<term>SARS Virus (metabolism)</term>
<term>Species Specificity</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Envelope Proteins (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Carboxypeptidases (métabolisme)</term>
<term>Coronavirus humain 229E (métabolisme)</term>
<term>Cytométrie en flux</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (métabolisme)</term>
<term>Humains</term>
<term>Infections à coronavirus (métabolisme)</term>
<term>Lignée cellulaire</term>
<term>Maladies de l'appareil respiratoire (virologie)</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Plasmides (génétique)</term>
<term>Protéines de l'enveloppe virale (métabolisme)</term>
<term>Récepteurs viraux (métabolisme)</term>
<term>Spécificité d'espèce</term>
<term>Tests de neutralisation</term>
<term>Virus du SRAS (métabolisme)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Carboxypeptidases</term>
<term>Membrane Glycoproteins</term>
<term>Receptors, Virus</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Plasmids</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Plasmides</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus 229E, Human</term>
<term>Coronavirus Infections</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Carboxypeptidases</term>
<term>Coronavirus humain 229E</term>
<term>Glycoprotéines membranaires</term>
<term>Infections à coronavirus</term>
<term>Protéines de l'enveloppe virale</term>
<term>Récepteurs viraux</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Maladies de l'appareil respiratoire</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Respiratory Tract Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Line</term>
<term>Flow Cytometry</term>
<term>Humans</term>
<term>Neutralization Tests</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Species Specificity</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Cytométrie en flux</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Spécificité d'espèce</term>
<term>Tests de neutralisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronavirus (CoV) infection of humans is usually not associated with severe disease. However, discovery of the severe acute respiratory syndrome (SARS) CoV revealed that highly pathogenic human CoVs (HCoVs) can evolve. The identification and characterization of new HCoVs is, therefore, an important task. Recently, a HCoV termed NL63 was discovered in patients with respiratory tract illness. Here, cell tropism and receptor usage of HCoV-NL63 were analyzed. The NL63 spike (S) protein mediated infection of different target cells compared with the closely related 229E-S protein but facilitated entry into cells known to be permissive to SARS-CoV-S-driven infection. An analysis of receptor engagement revealed that NL63-S binds angiotensin-converting enzyme (ACE) 2, the receptor for SARS-CoV, and HCoV-NL63 uses ACE2 as a receptor for infection of target cells. Potent neutralizing activity directed against NL63- but not 229E-S protein was detected in virtually all sera from patients 8 years of age or older, suggesting that HCoV-NL63 infection of humans is common and usually acquired during childhood. Here, we show that SARS-CoV shares its receptor ACE2 with HCoV-NL63. Because the two viruses differ dramatically in their ability to induce disease, analysis of HCoV-NL63 might unravel pathogenicity factors in SARS-CoV. The frequent HCoV-NL63 infection of humans suggests that highly pathogenic variants have ample opportunity to evolve, underlining the need for vaccines against HCoVs.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15897467</PMID>
<DateCompleted><Year>2005</Year>
<Month>08</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN>
<JournalIssue CitedMedium="Print"><Volume>102</Volume>
<Issue>22</Issue>
<PubDate><Year>2005</Year>
<Month>May</Month>
<Day>31</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.</ArticleTitle>
<Pagination><MedlinePgn>7988-93</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Coronavirus (CoV) infection of humans is usually not associated with severe disease. However, discovery of the severe acute respiratory syndrome (SARS) CoV revealed that highly pathogenic human CoVs (HCoVs) can evolve. The identification and characterization of new HCoVs is, therefore, an important task. Recently, a HCoV termed NL63 was discovered in patients with respiratory tract illness. Here, cell tropism and receptor usage of HCoV-NL63 were analyzed. The NL63 spike (S) protein mediated infection of different target cells compared with the closely related 229E-S protein but facilitated entry into cells known to be permissive to SARS-CoV-S-driven infection. An analysis of receptor engagement revealed that NL63-S binds angiotensin-converting enzyme (ACE) 2, the receptor for SARS-CoV, and HCoV-NL63 uses ACE2 as a receptor for infection of target cells. Potent neutralizing activity directed against NL63- but not 229E-S protein was detected in virtually all sera from patients 8 years of age or older, suggesting that HCoV-NL63 infection of humans is common and usually acquired during childhood. Here, we show that SARS-CoV shares its receptor ACE2 with HCoV-NL63. Because the two viruses differ dramatically in their ability to induce disease, analysis of HCoV-NL63 might unravel pathogenicity factors in SARS-CoV. The frequent HCoV-NL63 infection of humans suggests that highly pathogenic variants have ample opportunity to evolve, underlining the need for vaccines against HCoVs.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hofmann</LastName>
<ForeName>Heike</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Institute for Clinical and Molecular Virology and Nikolaus Fiebiger Center, University Erlangen-Nürnberg, 91054 Erlangen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pyrc</LastName>
<ForeName>Krzysztof</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>van der Hoek</LastName>
<ForeName>Lia</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Geier</LastName>
<ForeName>Martina</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Berkhout</LastName>
<ForeName>Ben</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pöhlmann</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2005</Year>
<Month>05</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D002268">Carboxypeptidases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber>
<NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002268" MajorTopicYN="N">Carboxypeptidases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D028941" MajorTopicYN="N">Coronavirus 229E, Human</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012140" MajorTopicYN="N">Respiratory Tract Diseases</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>5</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>5</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15897467</ArticleId>
<ArticleId IdType="pii">0409465102</ArticleId>
<ArticleId IdType="doi">10.1073/pnas.0409465102</ArticleId>
<ArticleId IdType="pmc">PMC1142358</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Med (Berl). 2003 Apr;81(4):227-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12700890</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Aug;77(16):8801-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12885899</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12995-3000</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14569023</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Mar 5;315(2):439-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14766227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2003 Dec;1(3):209-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15035025</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Apr;10(4):368-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15034574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Apr 9;304(5668):237-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15073366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Apr 23;279(17):17996-8007</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14754895</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6212-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15073334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2004 Jun;203(2):631-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15141377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Jul 9;319(4):1216-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15194496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2004 Aug 15;326(1):140-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15262502</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Sep;78(17):9007-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15308697</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Sep 3;321(4):994-1000</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15358126</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Oct;78(19):10628-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15367630</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem J. 2004 Oct 1;383(Pt 1):45-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15283675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Microbiol. 2004 Oct;12(10):466-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15381196</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Oct;78(20):11429-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15452268</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1992 Jun 4;357(6377):417-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1350661</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1992 Jun 4;357(6377):420-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1350662</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):492-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15655770</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):499-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15655771</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):503-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15655772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2005 Mar;75(3):463-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15648061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2005 Mar;75(3):455-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15648064</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2005 Feb 1;5:6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15686594</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2004;1:7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15548333</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Feb;74(3):1393-406</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10627550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2001 Jan 20;279(2):371-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11162792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2001 Dec;75(23):11583-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11689640</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Exp Med Biol. 2001;494:193-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11774468</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2002 Apr 25;296(1):177-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12036329</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2002 Jun 20;417(6891):822-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12075344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Bavière</li>
<li>District de Moyenne-Franconie</li>
</region>
<settlement><li>Erlangen</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Berkhout, Ben" sort="Berkhout, Ben" uniqKey="Berkhout B" first="Ben" last="Berkhout">Ben Berkhout</name>
<name sortKey="Geier, Martina" sort="Geier, Martina" uniqKey="Geier M" first="Martina" last="Geier">Martina Geier</name>
<name sortKey="Pohlmann, Stefan" sort="Pohlmann, Stefan" uniqKey="Pohlmann S" first="Stefan" last="Pöhlmann">Stefan Pöhlmann</name>
<name sortKey="Pyrc, Krzysztof" sort="Pyrc, Krzysztof" uniqKey="Pyrc K" first="Krzysztof" last="Pyrc">Krzysztof Pyrc</name>
<name sortKey="Van Der Hoek, Lia" sort="Van Der Hoek, Lia" uniqKey="Van Der Hoek L" first="Lia" last="Van Der Hoek">Lia Van Der Hoek</name>
</noCountry>
<country name="Allemagne"><region name="Bavière"><name sortKey="Hofmann, Heike" sort="Hofmann, Heike" uniqKey="Hofmann H" first="Heike" last="Hofmann">Heike Hofmann</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002685 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002685 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:15897467
   |texte=   Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:15897467" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki